CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

Airway Therapeutics secures $50m for Phase IIb/III zelpultide alfa trial

Phase 2zelpultide alfaPositive
AI Analysis

Summary

Airway Therapeutics secured $50 million in funding to support its Phase IIb/III trial of zelpultide alfa for prevention of bronchopulmonary dysplasia in very preterm infants.

Clinical Trial Data

Phase

IIb/III

Importance:6/10
Sentiment:
0.60
fundingclinical trialPhase IIb/IIIBPDrare disease
Related Companies

Read the original article

Published by Clinical Trials Arena on August 26, 2026 10:12 AM

Read Original